
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics is downgraded from a Buy to Hold following the failure of their pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia, which has resulted in the company shifting its focus towards cash preservation and exploring strategic alternatives. This failure has eliminated prior revenue projections and both primary and key secondary endpoints failed to reach statistical significance, indicating a significant risk and uncertainty in the company's clinical and regulatory prospects. Other risks, such as financing, commercialization, and potential litigation, could also contribute to further market share and valuation erosion.
Bears say
Quince Therapeutics is facing significant challenges as its Phase 3 study for eDSP, its lead candidate for A-T, failed to meet primary and key secondary endpoints. With the discontinuation of eDSP's development, the company's pipeline is limited and its investment thesis has shifted from clinical execution to balance sheet preservation. Quince's remaining cash and potential asset monetization will be the main drivers of shareholder value, but with no near-term catalysts, the risk-reward profile for the company is now focused on capital preservation rather than appreciation. The company is also facing challenges in its regulatory, commercial, and financial aspects, further adding to the uncertainty and risk for investors.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares